U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C14H20Br2N2.ClH
Molecular Weight 412.591
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BROMHEXINE HYDROCHLORIDE

SMILES

Cl.CN(CC1=C(N)C(Br)=CC(Br)=C1)C2CCCCC2

InChI

InChIKey=UCDKONUHZNTQPY-UHFFFAOYSA-N
InChI=1S/C14H20Br2N2.ClH/c1-18(12-5-3-2-4-6-12)9-10-7-11(15)8-13(16)14(10)17;/h7-8,12H,2-6,9,17H2,1H3;1H

HIDE SMILES / InChI
Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C14H20Br2N2
Molecular Weight 376.13
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including: http://www.drugsupdate.com/generic/view/745/Bromhexine | https://www.old.health.gov.il/units/pharmacy/trufot/alonim/5329.pdf | https://docetp.mpa.se/LMF/Bisolvon%20oral%20solution%20in%20sachet%20ENG%20PAR.pdf

Bromhexine is used for conditions where there are a lot of thick mucus in the airways. Bromhexine acts on the mucus at the formative stages in the glands, within the mucus-secreting cells. Bromhexine disrupts the structure of acid mucopolysaccharide fibres in mucoid sputum and produces a less viscous mucus, which is easier to expectorate. In addition, bromhexine has antioxidant properties. Occasional, mild side effects include: a feeling of fullness in the stomach (bloatedness), diarrhea, dizziness, headache, indigestion, nausea, sweating and skin rashes. Bromhexine may increase the concentration of concurrently administered antibiotics in bronchial secretions. No clinically relevant interactions with other medications have been reported.

CNS Activity

Originator

Keck, J.
2
Sources: DOI: 10.1002/jlac.19636620119
Curator's Comment: BE 625022

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Modulator
828
Modulator
828
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Approved
8429
Bisolvon

Approved Use

Secretolytic therapy in acute and chronic bronchopulmonary diseases associated with abnormal mucus secretion and impaired mucus transport.
PubMed

PubMed

TitleDatePubMed
Retrospective analysis of drug-induced urticaria and angioedema: a survey of 2287 patients.
2001 Nov
Ambroxol reduces LPS toxicity mediated by induction of alkaline phosphatases in rat lung.
2004 Aug
Synchronous germinomas in the pineal and suprasellar region.
2005 Apr
A case of a GH-producing pituitary adenoma associated with a unilateral headache with autonomic signs.
2005 Jun
Gastrointestinal stromal tumor in a child and review of the literature.
2005 Nov
Plant-based formulation in the management of chronic obstructive pulmonary disease: a randomized double-blind study.
2006 Jan
Colovesical fistula complicating diverticular disease: one-stage resection.
2006 Jan-Feb
Mediastinal extension of a complicated pancreatic pseudocyst; a case report and literature review.
2007 Apr 25
Simultaneous determination of salbutamol sulphate, bromhexine hydrochloride and etofylline in pharmaceutical formulations with the use of four rapid derivative spectrophotometric methods.
2007 Jul 30
Pharmacokinetic interaction between cefaclor and bromhexine in healthy Chinese volunteers.
2007 Oct
[Traumatic perforation of the duodenum--a case review].
2009 Feb
Feline calicivirus infection. ABCD guidelines on prevention and management.
2009 Jul
Feline herpesvirus infection. ABCD guidelines on prevention and management.
2009 Jul
[Pharmacological treatment of acute cough].
2009 May 14
Differential modulation of IgE-dependent activation of human basophils by ambroxol and related secretolytic analogues.
2009 Oct-Dec
Sensitive spectrophotometric method for quantitation of guaifenesin and dropropizine in their dosage forms.
2010
Tuberculosis should not be ignored in patients with peripheral gangrene.
2010 Dec
[Codeine and cutaneous drug reactions: Absence of cross-allergy with tramadol and fentanyl].
2010 May
[Juvenile Gougerot Sjögren syndrome: report of 3 cases].
2010 Nov
Contaminations of herbal products determined by NMR fingerprint.
2010 Sep
Patents

Patents

BE625022
2
JP2001226264A
5
JPS6344521A
2

Sample Use Guides

In Vivo Use Guide
8 to 16 mg three times daily
Route of Administration: Oral
In Vitro Use Guide
Bromhexine is shown to be scavengers of both superoxide and hydroxyl radicals. The dismutation of superoxide was accelerated 3-fold by bromhexine over the rate of spontaneous dismutation. The reaction constant of hydroxyl radicals with bromhexine was determined by competition kinetics to be 1.58 +/- 0.15 x 10(10) M-1S-1.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:08:32 GMT 2023
Edited
by admin
on Fri Dec 15 15:08:32 GMT 2023
Record UNII
YC2ZOM3Z8V
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BROMHEXINE HYDROCHLORIDE
EP   MART.   MI   USAN   WHO-DD  
USAN  
Official Name English
BENZENEMETHANAMINE, 2-AMINO-3,5-DIBROMO-N-CYCLOHEXYL-N-METHYL-, MONOHYDROCHLORIDE
Common Name English
BROMEHEXINE HYDROCHLORIDE
Common Name English
NA-274
Code English
BISOLVON
Brand Name English
N-CYCLOHEXYL-N-METHYL-(2-AMINO-3,5-DIBROMOBENZYL)AMMONIUM CHLORIDE
Systematic Name English
BROMHEXINE HYDROCHLORIDE [USAN]
Common Name English
BROMHEXINE HYDROCHLORIDE [JAN]
Common Name English
Bromhexine hydrochloride [WHO-DD]
Common Name English
NA 274
Code English
BROMHEXINE HYDROCHLORIDE [MI]
Common Name English
BROMHEXINE HYDROCHLORIDE [EP MONOGRAPH]
Common Name English
3,5-DIBROMO-N(SUP .ALPHA.)-CYCLOHEXYL-N(SUP .ALPHA.)-METHYLTOLUENE-.ALPHA.,2-DIAMINE MONOHYDROCHLORIDE
Systematic Name English
BROMHEXINE HCL
Common Name English
NSC-758383
Code English
BROMHEXINE HYDROCHLORIDE [MART.]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C74536
Created by admin on Fri Dec 15 15:08:32 GMT 2023 , Edited by admin on Fri Dec 15 15:08:32 GMT 2023
Code System Code Type Description
SMS_ID
100000091917
Created by admin on Fri Dec 15 15:08:32 GMT 2023 , Edited by admin on Fri Dec 15 15:08:32 GMT 2023
PRIMARY
NCI_THESAURUS
C142968
Created by admin on Fri Dec 15 15:08:32 GMT 2023 , Edited by admin on Fri Dec 15 15:08:32 GMT 2023
PRIMARY
NSC
758383
Created by admin on Fri Dec 15 15:08:32 GMT 2023 , Edited by admin on Fri Dec 15 15:08:32 GMT 2023
PRIMARY
EVMPD
SUB00875MIG
Created by admin on Fri Dec 15 15:08:32 GMT 2023 , Edited by admin on Fri Dec 15 15:08:32 GMT 2023
PRIMARY
DAILYMED
YC2ZOM3Z8V
Created by admin on Fri Dec 15 15:08:32 GMT 2023 , Edited by admin on Fri Dec 15 15:08:32 GMT 2023
PRIMARY
DRUG BANK
DBSALT001092
Created by admin on Fri Dec 15 15:08:32 GMT 2023 , Edited by admin on Fri Dec 15 15:08:32 GMT 2023
PRIMARY
PUBCHEM
5702220
Created by admin on Fri Dec 15 15:08:32 GMT 2023 , Edited by admin on Fri Dec 15 15:08:32 GMT 2023
PRIMARY
ECHA (EC/EINECS)
210-280-8
Created by admin on Fri Dec 15 15:08:32 GMT 2023 , Edited by admin on Fri Dec 15 15:08:32 GMT 2023
PRIMARY
RXCUI
1601
Created by admin on Fri Dec 15 15:08:32 GMT 2023 , Edited by admin on Fri Dec 15 15:08:32 GMT 2023
PRIMARY RxNorm
CHEBI
31303
Created by admin on Fri Dec 15 15:08:32 GMT 2023 , Edited by admin on Fri Dec 15 15:08:32 GMT 2023
PRIMARY
EPA CompTox
DTXSID0045886
Created by admin on Fri Dec 15 15:08:32 GMT 2023 , Edited by admin on Fri Dec 15 15:08:32 GMT 2023
PRIMARY
FDA UNII
YC2ZOM3Z8V
Created by admin on Fri Dec 15 15:08:32 GMT 2023 , Edited by admin on Fri Dec 15 15:08:32 GMT 2023
PRIMARY
ChEMBL
CHEMBL253376
Created by admin on Fri Dec 15 15:08:32 GMT 2023 , Edited by admin on Fri Dec 15 15:08:32 GMT 2023
PRIMARY
CAS
611-75-6
Created by admin on Fri Dec 15 15:08:32 GMT 2023 , Edited by admin on Fri Dec 15 15:08:32 GMT 2023
PRIMARY
MERCK INDEX
m2668
Created by admin on Fri Dec 15 15:08:32 GMT 2023 , Edited by admin on Fri Dec 15 15:08:32 GMT 2023
PRIMARY Merck Index
Related Record Type Details
Structure of BROMHEXINE
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of BROMHEXINE
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966